| Prev Close | 63.01 |
| Open | 62.79 |
| Day Low/High | 62.17 / 63.27 |
| 52 Wk Low/High | 56.56 / 85.97 |
| Volume | 2.72M |
Gilead Sciences, Inc. (GILD)
62.92
0.09
0.14
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 1256.59B |
| Market Cap | 78.49B |
| P/E Ratio | 68.31 |
| Div & Yield | N.A. (N.A) |
Real Money Post-Industrial Average Feels the Pain, But Continues to Outperform
For March and the first quarter, the RMPIA takes less of a hit than major indexes.
Jim Cramer: Here Are the Quarter's Winners, Losers
The five best performing and worst performing stocks in the S&P 500 in the previous quarter pretty much tells the tale of the tape, so here goes.
Jim Cramer: Here's the Science Behind Our Rally
While Johnson & Johnson and other pharma cos. give us hope, here's my wish list to keep the nation safe and the economy ready to go again.
In a Post-Coronavirus World, Put This Lesser-Known Stock on Your List
Things will be different after Covid-19 and one change will be in how people care about themselves.
3 Japanese Stocks Getting a Boost on Potential Coronavirus Treatments
Japan is a leader in pharmaceuticals and has three companies working overtime to develop treatments for Covid-19.
A Look at Our Situation Now: Good, Bad, and Ugly, and 3 New Stock Groups
Consider these stock model ideas: virus groups, work remotely, and fiscal.
Failed Rallies, Semiconductors Rising and the Fed's Big Guns
The Fed has attacked developing problems in real-time -- and as China shows signs of life, the semi stocks are benefitting.
Licking Our Wounds and Waiting to See How the Covid-19 Story Plays Out
The next four to six weeks could determine whether the U.S. economy can recover from the coronavirus crisis without lasting damage
Mild Good News as Japanese Flu Drug Shows Promise in Mild Covid-19 Cases
Fujifilm Holdings has a promising drug that seems to work in improving the outcome for coronavirus patients in China and Japan, though Avigan is a treatment not a cure.
Keeping Sane, the Profitable Way: How I'm Playing This Market
I continue to shuttle new money into the market on declines using buy-write option strategies.
The Fed's Big Bazooka, Covid-19 Treatments, Market Breather
Amid dramatically rising jobless claims, the Fed continues to fire big bullets, the Senate is pushing its economic support package and Gilead and Regeneron have made progress on coronavirus treatments.
These Are the Times We Live In
Here again is my approach and my three stock groups: 'rebound', 'revenue' and 'virus'.
The Magic Mice of Regeneron
I am pretty well covered in my 'virus group'. I could definitely see bringing a few shares of REGN on board the next time the algorithms include that name in a broad selloff. Not before.
Volatility Yes, but There's Positive News Too
The market has gained some momentum. It looks like the administration might be readying to declare a national emergency. The president is scheduled to make comments starting an hour before the market close. I expect equities to continue to be volati...
5 Leading Biotechs in Search of a Coronavirus Vaccine
The race is on. The prize could be countless lives saved and perhaps billions of dollars in revenue.
Early Rebound
Markets look like they will see a substantial rebound today, at least in the early going. S&P 500 futures are up some 5% just before the market opens. Gilead Sciences  just reported encouraging results around its experimental antiviral Remdesivir in...
Will Gilead Sciences Remdesivir Help Arrest the Coronavirus?
Right now, GILD holds a strictly defensive spot among my holdings.
Coronavirus Impact Spreads, Market Selloff, Fed Action, Risk Tolerance
What came first? The chicken or the egg? The bear market or the pandemic? I don't care much for labels.
Don't Do the Coronavirus Chase
There are small vaccine and testing companies that see their shares spike when a new virus hits, but whether those gains will last is questionable.
The Oil Factor, 50 Year Bonds, Trading Clorox and Gilead Sciences: Market Recon
The question begs... 'Do significantly lower oil prices provoke increased demand?' Anywhere?
Jim Cramer: Rate Cut No Cure for Coronavirus
But don't throw up your arms yet -- here are names that could be golden opportunities.
Roller Coaster Markets, Time for Emergency Measures, 3 Stock Groups to Focus On
I'll stick to the three-pronged approach... the Rebound group, the Virus group, and the Revenue group.
Market Outflows, Unknown Earnings Expectations and Trading Notes: Market Recon
Here are a number of things that I'm watching now.
Playing the Hand You're Dealt
Check out just a few of the year-to-date moves coming into Thursday on 8 companies you've never heard of before the last week or two.
Jim Cramer: We're Not Yet Inured to Coronavirus Disappointment
Microsoft says it will miss its personal computer forecast, but Marriott appears to be trading up a tad.
Moderna Could Spike Much Higher as the Pandemic Story Plays Out
Hot money will be attracted to stocks that show promise in dealing with the coronavirus.
Jim Cramer: 3 Market Storylines Are In Play, But Which Is Best for Investors?
Only one of these scenarios is going to get you in and out of this market with your assets intact and your portfolio stronger.
Jim Cramer: Hope for the Best, Plan for the Worst
Is this the end of the world? No. You still need to plan for your financial well-being, even as the CDC tells us 'this might be bad.'
